Eric Vachon on the Effect of Complexity on Adherence with Kinase Inhibitors

Video

Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.

Eric Vachon, BSN, PhD candidate, Michigan State University, discusses the many variables of complexity that can effect adherence to kinase inhibitors.

The regimen for kinase inhibitors is the most complex. Many current studies focus only on the issue of continuous versus cycling. However, there are other considerations that Vachon is studying in his own research.

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
5 experts in this video
5 experts in this video
Screen capture of Seth Eisenberg, ASN, RN, OCN, BMTCN, on a video call with an Oncology Nursing News branded border around the frame
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
Related Content
Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Simple line illustration of breast tissue on a yellow background

PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

Roman Fabbricatore
February 10th 2025
Article

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.